|
Dr. Dorsam has been an active member of a group of physicians, biologists, molecular
immunologists, oncologists, and veterinarians searching for clues to the cures for cancer
(and other chronic diseases). The Institute for Therapeutic Discovery (TITD) is that group of
individuals.
Almost thirty years ago, research delved into the reasons why fetuses are not affected by
their mother's cancer. A hormone, made by the mother's placenta, called human chorionic
gonadotropin (hCG) was found to increase apoptosis of cancer cells in tissue cultures. When
hCG was incubated with various cancer cell lines in the laboratory, the cells reverted to
normal and died (apoptosis). Other laboratory studies, throughout the last few years, have
shown that hCG has an impact on certain genes within cells that regulate cell growth and
signals for cell death. Our research has shown, specifically, which genes are affected.
In the research fifty years ago concerning tuberculosis, an immune stimulant was identified:
Bacillus-Calmette-Guerin. BCG in both high and low doses affects the general immune system
helping fight bacteria, viruses, and cancers. Our use identified that very low doses was
extremely helpful in "up regulating" certain helpful proteins, called cytokines, and "down
regulating" certain inflammatory or harmful cytokines. Low dose therapy also helps the
patient avoid harmful side effects.
A protein, called Interferon was discovered many years ago. Interferon has been used to fight
viruses and cancers. Interferon-alpha, one of the many kinds of Interferon, has been shown to
have high anti-cancer properties.
In TITD's formula for cancer, we have combined these three molecules. Our molecular signal is
called: LDI with Interferon-alpha. Previous "batches" of LDI did not include Interferon. Dr.
Dorsam, in his literature review and research, added Interferon for treating his patients
with cancer. LDI with Interferon-alpha has been used, clinically, for three to four years.
Our experience has shown that use of LDI in cancer patients has been very helpful in
extending the patient's life expectancy with quality.
A clinical trial using TITD's LDI with Interferon-alpha was performed at the University of
Missouri's School of Veterinary Medicine. Researchers there compared the use and effects of
LDI vs. a conventional chemotherapy drug, called vincristine. The trial resulted in showing
that LDI was as effective in preventing cancer recurrences in dogs diagnosed with Grade II-III
Mast Cell Tumors (MCT). The interesting phenomenon concerning LDI is that there are no side
effects as opposed to Vincristine's significant side effects...
Our use of "experimental" medications complements conventional therapies, and we, in no way,
encourage our patient's owners to not seek conventional therapies for cancer.
We sit down with every "parent" of a cancer patient, explaining how LDI works, routes of
administration, We dispense the molecule at no charge to the client. We continue to monitor
the patient throughout the course of disease, including blood work, radiography, etc. when
necessary. We cooperate and collaborate with specialists and other local practitioners to
ensure the best of care for the cancer patient.
We are most happy to share our information with pet owners concerning use of LDI and
encourage them to look further into TITD (www.titd.org) and the research that we are involved
in. Or you may call our office for a consultation.
|
